Company
Viatris Inc.
Headquarters: Canonsburg, PA, United States
Founded: November 16, 2020
Employees: 37,000
CEO: Mr. Michael Goettler
Market Cap
$13.86 Billion
USD as of Jan. 1, 2024
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Top 1-year algo backtest: +298.72%
$10,000 in April 2023 would now be $39,872 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Viatris Inc. has the following listings and related stock indices.
Stock: NASDAQ: VTRS wb_incandescent
Stock: BMV: VTRS wb_incandescent
Stock: FSX: VIA wb_incandescent
Stock: MTA: VTRS wb_incandescent
Stock: Munich: VIA wb_incandescent
Stock: XETR: VIA wb_incandescent
Product & Services
Branded and generic pharmaceuticals and active pharmaceutical ingredients
Key People
Robert J. Coury (Executive Chairman) Michael Goettler (CEO) Sanjeev Narula (CFO) W. Don Cornwell (Director) James M. Kilts (Director) Ian Read (Director)
Financials
Revenue: US$11.946 billion (2020)
Net income: US$0.670 billion (2020)
Total assets: US$61.553 billion (2020)
Total equity: US$22.951 billion (2020)